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T
he disease dengue fever
(DF; also known as break-
bone fever, dandy fever, and
by other names) can be caused
by any of 4 viruses within the
virus family Flaviviridae,
genus Flavivirus, i.e., dengue
virus types 1–4 (DENV-1–4).
Dengue fever is a short-dura-
tion, nonfatal illness character-
ized by sudden onset of
headache, retroorbital pain,
and high fever, joint pain, and rash. Whereas uncomplicat-
ed DF usually is the case, the picture can be much darker
than that. Through a mechanism known as immune
enhancement, sequential infections with certain dengue
viruses set the stage for a far more serious complication,
dengue hemorrhagic fever (DHF) and dengue shock syn-
drome, so that having uncomplicated DF can presage hav-
ing DHF (1).
DHF is characterized by high fever, vascular perme-
ability, bleeding, enlargement of the liver, and circulatory
failure (dengue shock syndrome). In mild or moderate
cases, signs and symptoms subside after the fever subsides,
but in severe cases the patient’s condition suddenly deteri-
orates, body temperature decreases, and the circulatory
system begins to fail. The patient then may quickly go into
shock and die within a day, or quickly recover, if volume
therapy is instituted (2).
Dengue viruses are transmitted from person to person
or from monkey to monkey through infected female mos-
quitoes of the genus Aedes. The mosquito acquires the
virus by taking a blood meal from an infected human, the
principal amplifying host for these viruses, or from an
infected monkey. Humans circulate these viruses in their
blood (viremia) for 7 to 10 days after infection, allowing
ample time for mosquitoes, often many mosquitoes, to
feed and become infected. After an intrinsic incubation
period of 1 week to 10 days, the mosquito is capable of
transmitting the virus to a new host while blood feeding.
During epidemics of dengue, attack rates may be
80%–90% in susceptible persons. Although, it is not usu-
ally recognized, more than half the people who are infect-
ed with a dengue virus may be asymptomatic, which
would indicate a substantial underreporting of infections.
These comprise a substantial number of people who may
have been primed for more serious illness at a later date
and are unaware of their situation.
The global prevalence of dengue has increased substan-
tially recently. Dengue is endemic in ≥100 countries in
Southeast Asia, Africa, the Western Pacific, the Americas,
Africa, and the eastern Mediterranean area (available from
http://www.who.int/mediacentre/factsheets/fs117/en/),
with imported cases essentially everywhere tourists, busi-
ness people, and military personnel travel, whether dengue
is recognized there or not. More than 2 billion of the
approximately 6.5 billion inhabitants of this planet are at
risk of acquiring dengue, and the World Health
Organization has estimated that “there may be 50 million
cases of dengue infection worldwide every year” (avail-
able from http://www.who.int/mediacentre/factsheets/
fs117/en/). However, this is a misstatement. Either there
are 50 million dengue infections (some with illness, some
not) or there are 50 million people sick with dengue each
year. Infections are not the same as illnesses.
The mild form of dengue is a serious annoyance and
often is painful for those with it. However, DHF is the
major international public health concern. Before 1970, a
total of 9 countries had reported DHF epidemics; by 1995,
>4 times that number reported such outbreaks. Most of
these countries are in Southeast Asia and the Western
Pacific, but with the worldwide spread of all dengue types,
this disease threatens residents in tropical and subtropical
regions, predominantly in urban and semiurban areas. In
2001,  ≥600,000 cases of dengue were reported in the
Americas, of which 15,000 were cases of DHF, more than
twice the number of DHF cases in the Americas in 1995
(available from http://www.who.int/mediacentre/fact-
sheets/fs117/en/). In 2001 alone, Brazil reported nearly
400,000 cases, including 670 cases of DHF. Not only is the
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ousness of its complications is being recognized (available
from http://www.cdc.gov/search.do?action=search&query
Text=dengue). An estimated 500,000 persons with DHF
require hospitalization each year, a substantial proportion
of whom are children. Tragically, DHF is a leading cause
of hospitalization and death of children in several Asian
countries. Case-fatality rates can exceed 20%, are usually
2.5%, but can be reduced to <1% with rapid recognition
and proper treatment.
In countries that are prepared for dengue and its com-
plications, diagnostic services are available. We are able to
sequence these viruses and determine their origins and
evolutionary determinants. We can, to some degree, con-
trol the vector mosquitoes (Aedes aegypti and Ae. albopic-
tus). Our knowledge of the pathophysiology of DHF is
quite sophisticated (2,3). Avast literature is available about
these viruses and the diseases they cause. Why, then, does
dengue continue to spread? If we cannot eradicate dengue
(and its vector Ae. aegypti) from populations on islands,
from where can we eradicate it? Politics or misdirected
funding, as always, has something to do with this, but the
situation is much more complicated than that. Unless
transovarial transmission (passage of virus from female to
offspring through the egg) is much more important than it
appears to be, other mechanisms are at play. Univalent
vaccines for these viruses have been prepared but, for the
most part, health authorities are (justifiably) unwilling to
use such vaccines because they have the potential to stim-
ulate the production of antibodies, which would prime vac-
cinees for DHF by immune enhancement. Fortunately,
novel approaches (development of incompetent mosqui-
toes), development of modern tetravalent vaccines, and
development of chimeric vaccine viruses (4), using classic
as well as molecular approaches will soon be available and
hold out promise of tools we need to eliminate or eradicate
this scourge.
This issue of Emerging Infectious Diseases includes
some very interesting reports on dengue and its clinical
complications, dengue diagnosis, and dengue epidemiolo-
gy. These add considerably to the scientific record.
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